New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 27, 2012
12:19 EDTDECK, MDRX, BAYRY, WCRX, JAZZ, CVH, SIMO, MXWL, CERN, CRAY, EXPE, SBUX, F, MRK, CVX, PG, AMZNOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday, in spite of Spain's ratings being cut by S&P and a U.S. GDP reading that disappointed. Each of the major indices is higher, with the Nasdaq the leader. The averages have moved in a narrow range since the open as market participants digest all the earnings and economic news that was delivered this week. Earnings have come in better than expected, which has led the averages to rebound and stand ready for a positive close for the week. The economic data remains mixed, as housing and labor continue to limp along but consumer confidence is showing an uptick. For now earnings have trumped macro data, leading to a move higher for equities... ECONOMIC EVENTS: In the U.S., gross domestic product reportedly grew at an annual rate of 2.2% in the first quarter, versus an expected increase of 2.5%. Personal consumption increased 2.9%, versus expectations for an increase of 2.3%. The University of Michigan Consumer Confidence report had a reading of 76.4, versus the expected 75.7. Regarding Europe, S&P cut its credit rating on Spain to BBB+ from A and said its long-term outlook is negative... COMPANY NEWS: Amazon.com (AMZN), Ford (F) and Starbucks (SBUX) all exceeded expectations on the top and bottom lines, but only Amazon was rewarded by investors. Shares of the internet giant advanced more than 14% on the heels of upgrades from Goldman, Merrill Lynch, Nomura and Sun Trust on its strong results... The three Dow components reporting earnings, Chevron (CVX), Merck (MRK) and Procter & Gamble (PG), all declined in spite of the fact that each beat consensus earnings expectations. P&G was the Dow's worst performer, sliding 3.5%, after lowering its outlook for next quarter... Among the many other companies reporting earnings, advancers included Expedia (EXPE), Cray (CRAY) and Cerner (CERN); decliners included Maxwell (MXWL), Silicon Motion (SIMO) and Coventry Health (CVH)... MAJOR MOVERS: Among the notable gainers were Jazz Pharmaceuticals (JAZZ), up over 15%, after announcing plans to acquire EUSA Pharma for $650M, and Warner Chilcott (WCRX), up 9%, after the Times of London said that Bayer (BAYRY) may offer $32 per share for the company. Noteworthy losers included Allscripts (MDRX), down 41%, following downgrades by at least eight firms after its earnings and guidance severely missed consensus and the company reported the ouster of its board chairman, three other board members and its CFO, and Deckers Outdoor (DECK), down more than 25%, after lowering its full year sales and profit outlook... INDICES: Near noon, the Dow was up 30.92, or 0.23%, to 13,235.54; the Nasdaq was up 14.12, or 0.46%, to 3,064.73; and the S&P 500 was up 2.31, or 0.17%, to 1,402.29.
News For AMZN;PG;CVX;MRK;F;SBUX;EXPE;CRAY;CERN;MXWL;SIMO;CVH;JAZZ;WCRX;BAYRY;MDRX;DECK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
September 18, 2014
16:00 EDTAMZNOptions Update; September 18, 2014
Subscribe for More Information
09:50 EDTMXWLMaxwell management to meet with Northland
Meetings to be held in Chicago on September 22 and in Milwaukee on September 23 hosted by Northland.
08:48 EDTMRKNeogen's dairy genomic program to be marketed by Merck
Subscribe for More Information
08:44 EDTAMZNAmazon.com volatility flat into Alibaba IPO
Subscribe for More Information
06:20 EDTBAYRYBayer to float MaterialScience as separate company
Subscribe for More Information
06:05 EDTAMZNAmazon partners with Bango, Telefonica Deutschland on carrier billing services
Subscribe for More Information
06:00 EDTAMZNAmazon introduces Fire OS 4 'Sangria'
Subscribe for More Information
05:59 EDTAMZNAmazon announces new Fire HD
Subscribe for More Information
05:57 EDTAMZNAmazon introduces Fire HDX 8.9
Amazon introduced the all-new Fire HDX 8.9, which combines a light design and HDX display with a new, more powerful processor, exclusive Dolby Atmos and the latest Dolby Audio, and all-new Fire OS 4 “Sangria” features and services. The new Fire HDX is available for pre-order starting today for $379.
05:57 EDTAMZNAmazon announces Fire HD Kids Edition
Subscribe for More Information
05:56 EDTAMZNAmazon introduces two new Kindles
Amazon introduced the 7th generation of Kindle: Kindle Voyage and the new $79 Kindle, with a 20% faster processor, twice the storage, and now with a touch interface. Kindle Voyage features an all-new design, with a beautiful flush glass front and a magnesium back. Kindle Voyage uses a brand new Paperwhite display, with the highest resolution, highest contrast, and highest brightness of any Kindle. The new Kindle is available for pre-order today for $79 and will start shipping in October. The new Kindle Voyage is $199 and is available for pre-order and will start shipping in October.
05:51 EDTAMZNPiper questions why Amazon is in hardware business
Subscribe for More Information
September 17, 2014
18:13 EDTAMZNBoeing, Lockheed Martin to team with Bezos firm on rocket engine, WSJ reports
Subscribe for More Information
17:44 EDTBAYRYBayer plans separation of MaterialsSciences unit, WSJ says
Subscribe for More Information
16:00 EDTAMZNOptions Update; September 17, 2014
iPath S&P 500 VIX Short-Term Futures down 24c to 27.63. Option volume leaders: AAPL TSLA BAC TWTR AMZN X WLT KO PBR according to Track Data.
09:55 EDTSIMOSilicon Motion upgraded to Buy from Hold at Standpoint Research
Subscribe for More Information
09:33 EDTMRKMerck announced positive results from Phase 3 data for omarigliptin
Subscribe for More Information
08:31 EDTMRKMerck, Sun Pharma enter into licensing agreement for Tildrakizumab
Merck and Sun Pharmaceutical Industries, through their respective subsidiaries,announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80M. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product. Merck is eligible to receive undisclosed payments associated with regulatory and sales milestones, as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales. The transaction is subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.
07:37 EDTFEU car registrations up 2.1% in August, up 5.6% in July
The European Automobile Manufacturers Association reported new passenger car registrations were up by 5.6% in July and by 2.1% in August. Eight months into the year, demand for new cars amounted to 8,336,159 units, or 6.0% more than in the same period last year, the group noted. Publicly traded automakers include Fiat (FIATY), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), Toyota (TM) and Volkswagen (VLKAY).
06:59 EDTAMZNAmazon.com ads could increase EPS, says Pacific Crest
Pacific Crest believes that Amazon.com's ad initiatives could boost its EPS by $2.60 and raise its operating margin by one point in 2018. The firm quotes ad tech experts with whom it spoke as saying that the company is "a potential juggernaut in the ad industry" and is "on a $1B run rate." The firm keeps a $460 price target and Outperform rating on the shares.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use